Abstract
RNA interference (RNAi) is a powerful tool to silence gene expression post-transcriptionally1. However, its potential to treat or prevent disease remains unproven. Fas-mediated apoptosis is implicated in a broad spectrum of liver diseases, where inhibiting hepatocyte death is life-saving2. We investigated the in vivo silencing effect of small interfering RNA (siRNA) duplexes targeting the gene Fas (also known as Tnfrsf6), encoding the Fas receptor, to protect mice from liver failure and fibrosis in two models of autoimmune hepatitis. Intravenous injection of Fas siRNA specifically reduced Fas mRNA levels and expression of Fas protein in mouse hepatocytes, and the effects persisted without diminution for 10 days. Hepatocytes isolated from mice treated with Fas siRNA were resistant to apoptosis when exposed to Fas-specific antibody or co-cultured with concanavalin A (ConA)-stimulated hepatic mononuclear cells. Treatment with Fas siRNA 2 days before ConA challenge abrogated hepatocyte necrosis and inflammatory infiltration and markedly reduced serum concentrations of transaminases. Administering Fas siRNA beginning one week after initiating weekly ConA injections protected mice from liver fibrosis. In a more fulminant hepatitis induced by injecting agonistic Fas-specific antibody, 82% of mice treated with siRNA that effectively silenced Fas survived for 10 days of observation, whereas all control mice died within 3 days. Silencing Fas expression with RNAi holds therapeutic promise to prevent liver injury by protecting hepatocytes from cytotoxicity.
This is a preview of subscription content, access via your institution
Access options
Subscribe to this journal
Receive 12 print issues and online access
$209.00 per year
only $17.42 per issue
Rent or buy this article
Prices vary by article type
from$1.95
to$39.95
Prices may be subject to local taxes which are calculated during checkout
Similar content being viewed by others
Change history
14 February 2003
This was incorrect in AOP version but corrected in print. Changed one word in the legend, as per the note.
Notes
NOTE: In the version of this article initially published online, the Fig. 1 legend contained an error. The third sentence of (b) should read, "...housekeeping genes (L32 and Gapd) were unaffected..." This mistake has been corrected for the HTML and print versions of the article.
References
Hannon, G.J. RNA interference. Nature 418, 244–251 (2002).
Rust, C. & Gores, G.J. Apoptosis and liver disease. Am. J. Med. 108, 567–574 (2000).
Elbashir, S.M. et al. Duplexes of 21-nucleotide RNAs mediate RNA interference in cultured mammalian cells. Nature 411, 494–498 (2001).
Caplen, N.J., Parrish, S., Imani, F., Fire, A. & Morgan, R.A. Specific inhibition of gene expression by small double-stranded RNAs in invertebrate and vertebrate systems. Proc. Natl. Acad. Sci. USA 98, 9742–9747 (2001).
McCaffrey, A.P. et al. RNA interference in adult mice. Nature 418, 38–39 (2002).
Lewis, D.L., Hagstrom, J.E., Loomis, A.G., Wolff, J.A. & Herweijer, H. Efficient delivery of siRNA for inhibition of gene expression in postnatal mice. Nat. Genet. 32, 107–108 (2002).
Xia, H., Mao, Q., Paulson, H.L. & Davidson, B.L. siRNA-mediated gene silencing in vitro and in vivo. Nat. Biotechnol. 20, 1006–1010 (2002).
Kondo, T., Suda, T., Fukuyama, H., Adachi, M. & Nagata, S. Essential roles of the Fas ligand in the development of hepatitis. Nat. Med. 3, 409–413 (1997).
Siegel, R.M. & Fleisher, T.A. The role of Fas and related death receptors in autoimmune and other disease states. J. Allergy Clin. Immunol. 103, 729–738 (1999).
Ogasawara, J. et al. Lethal effect of the anti-Fas antibody in mice. Nature 364, 806–809 (1993).
Li, X.K. et al. Fulminant hepatitis by Fas-ligand expression in MRL-lpr/lpr mice grafted with Fas-positive livers and wild-type mice with Fas-mutant livers. Transplantation 71, 503–508 (2001).
Canbay, A. et al. Fas enhances fibrogenesis in the bile duct ligated mouse: a link between apoptosis and fibrosis. Gastroenterology 123, 1323–1330 (2002).
Zhang, G., Budker, V. & Wolff, J.A. High levels of foreign gene expression in hepatocytes after tail vein injections of naked plasmid DNA. Hum. Gene Ther. 10, 1735–1737 (1999).
Zhang, H. et al. Reduction of liver Fas expression by an antisense oligonucleotide protects mice from fulminant hepatitis. Nat. Biotechnol. 18, 862–867 (2000).
Bertrand, J. et al. Comparison of antisense oligonucleotides and siRNAs in cell culture and in vivo. Biochem. Biophys. Res. Commun. 296, 1000–1004 (2002).
Schwarz, D.S., Hutvagner, G., Haley, B. & Zamore, P.D. Evidence that siRNAs function as guides, not primers, in the Drosophila and human RNAi pathways. Mol. Cell 10, 537–548 (2002).
Ketting, R.F. et al. Dicer functions in RNA interference and in synthesis of small RNA involved in developmental timing in C. elegans. Genes Dev. 15, 2654–2659 (2001).
Lipardi, C., Wei, Q. & Paterson, B.M. RNAi as random degradative PCR: siRNA primers convert mRNA into dsRNAs that are degraded to generate new siRNAs. Cell 107, 297–307 (2001).
Takahashi, T. et al. Generalized lymphoproliferative disease in mice, caused by a point mutation in the Fas ligand. Cell 76, 969–976 (1994).
Ryo, K. et al. Significance of Fas antigen-mediated apoptosis in human fulminant hepatic failure. Am. J. Gastroenterol. 95, 2047–2055. (2000).
Faouzi, S. et al. Anti-Fas induces hepatic chemokines and promotes inflammation by an NF-κB-independent, caspase-3-dependent pathway. J. Biol. Chem. 276, 49077–49082 (2001).
Seino, K. et al. Contribution of Fas ligand to T cell-mediated hepatic injury in mice. Gastroenterology 113, 1315–1322 (1997).
Takeda, K. et al. Critical contribution of liver natural killer T cells to a murine model of hepatitis. Proc. Natl. Acad. Sci. USA 97, 5498–5503 (2000).
Miyazawa, Y., Tsutsui, H., Mizuhara, H., Fujiwara, H. & Kaneda, K. Involvement of intrasinusoidal hemostasis in the development of concanavalin A-induced hepatic injury in mice. Hepatology 27, 497–506 (1998).
Galle, P.R. et al. Involvement of the CD95 (APO-1/Fas) receptor and ligand in liver damage. J. Exp. Med. 182, 1223–1230 (1995).
Takahashi, S. & Lee, M.J. Collagen metabolism in fibrotic liver. Effects of concanavalin A and aggregated myeloma immunoglobin G. Biochem. J. 241, 49–54 (1987).
Badawy, A.A. et al. Evaluation of colchicine with or without praziquantel therapy in the control of hepatic fibrosis in murine schistosomiasis. Pharmacol. Res. 33, 319–325 (1996).
Dhiman, R.K., Seth, A.K., Jain, S., Chawla, Y.K. & Dilawari, J.B. Prognostic evaluation of early indicators in fulminant hepatic failure by multivariate analysis. Dig. Dis. Sci. 43, 1311–1316 (1998).
Klauning, J.E. et al. Mouse liver cell culture. 1. Hepatocyte isolation. In Vitro 17, 913–925 (1981).
Kimura, K. et al. Immunopathogenesis of hepatic fibrosis in chronic liver injury induced by repeatedly administered concanavalin A. Int. Immunol. 11, 1491–1500 (1999).
Acknowledgements
This work was supported by US National Institutes of Health grants AI42510 and AI45406 (J.L.), AI49792 and AI45306 (P.S.), American Foundation for AIDS Research (AmfAR) grants 70589-32-RF (S.L.) and 70540-30-RF (N.I.), Guangdong Provincial Natural Science Foundation grants 980098 (E.S.) and 001359 (J.M.), and National Natural Scientific Foundation of China grants 39670705 (J.C.), 39700135 and 39970718 (J.M.).
Author information
Authors and Affiliations
Corresponding author
Ethics declarations
Competing interests
The authors declare no competing financial interests.
Rights and permissions
About this article
Cite this article
Song, E., Lee, SK., Wang, J. et al. RNA interference targeting Fas protects mice from fulminant hepatitis. Nat Med 9, 347–351 (2003). https://doi.org/10.1038/nm828
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1038/nm828
This article is cited by
-
Nanomedicine for autophagy modulation in cancer therapy: a clinical perspective
Cell & Bioscience (2023)
-
Emerging nanobiotechnology for precise theranostics of hepatocellular carcinoma
Journal of Nanobiotechnology (2022)
-
A dual-specific CRISPR-Cas nanosystem for precision therapeutic editing of liver disorders
Signal Transduction and Targeted Therapy (2022)
-
Therapeutic approaches targeting CD95L/CD95 signaling in cancer and autoimmune diseases
Cell Death & Disease (2022)
-
shRNA transgenic swine display resistance to infection with the foot-and-mouth disease virus
Scientific Reports (2021)